Reaction
Immune-Mediated Thyroiditis reporting signals
As of the last recalculation, Immune-Mediated Thyroiditis appears in 463 FAERS reports alongside 12 co-occurring drug terms. The strongest observed disproportionality signal is PEMBROLIZUMAB (PRR 215.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pembrolizumab | 242 | 215.5 | 216.0 |
| Ipilimumab | 128 | 183.9 | 184.4 |
| Nivolumab | 180 | 136.3 | 136.6 |
| Lenvatinib | 31 | 45.5 | 45.5 |
| Durvalumab | 16 | 36.6 | 36.6 |
| Pemetrexed | 16 | 34.7 | 34.7 |
| Carboplatin | 79 | 33.5 | 33.5 |
| Paclitaxel (Aibumin-Bound) | 46 | 27.8 | 27.8 |
| Paclitaxel | 46 | 23.1 | 23.1 |
| Atezolizumab | 19 | 22.9 | 22.9 |
| Granisetron | 5 | 21.7 | 21.7 |
| Pemetrexed Disodium | 16 | 19.5 | 19.5 |